Logo image of BDTX

BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Fundamental Analysis

NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock - Currency: USD

2.055  -0.11 (-5.3%)

Fundamental Rating

2

BDTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While BDTX seems to be doing ok healthwise, there are quite some concerns on its profitability. BDTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDTX had negative earnings in the past year.
In the past year BDTX has reported a negative cash flow from operations.
BDTX had negative earnings in each of the past 5 years.
In the past 5 years BDTX always reported negative operating cash flow.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -53.01%, BDTX perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
With a Return On Equity value of -75.03%, BDTX perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
ROA -53.01%
ROE -75.03%
ROIC N/A
ROA(3y)-53.68%
ROA(5y)-40.74%
ROE(3y)-71.18%
ROE(5y)-51.67%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BDTX has been increased compared to 1 year ago.
Compared to 5 years ago, BDTX has more shares outstanding
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.09, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
BDTX has a Altman-Z score (-4.09) which is in line with its industry peers.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.09
ROIC/WACCN/A
WACCN/A
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

BDTX has a Current Ratio of 5.55. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
BDTX's Current ratio of 5.55 is in line compared to the rest of the industry. BDTX outperforms 58.47% of its industry peers.
BDTX has a Quick Ratio of 5.55. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
BDTX has a Quick ratio (5.55) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.55
Quick Ratio 5.55
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.56% over the past year.
EPS 1Y (TTM)37.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.11% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.47%
EPS Next 2Y15.61%
EPS Next 3Y5.67%
EPS Next 5Y9.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.61%
EPS Next 3Y5.67%

More info and screens

0

5. Dividend

5.1 Amount

BDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (2/25/2025, 3:48:02 PM)

2.055

-0.11 (-5.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-12 2025-03-12/amc
Inst Owners97.65%
Inst Owner Change-98.22%
Ins Owners0.94%
Ins Owner Change2.73%
Market Cap116.29M
Analysts86.15
Price Target14.79 (619.71%)
Short Float %12.88%
Short Ratio8.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.7%
Min EPS beat(2)8.83%
Max EPS beat(2)26.57%
EPS beat(4)4
Avg EPS beat(4)21.25%
Min EPS beat(4)8.83%
Max EPS beat(4)28.47%
EPS beat(8)8
Avg EPS beat(8)14.38%
EPS beat(12)12
Avg EPS beat(12)14.36%
EPS beat(16)14
Avg EPS beat(16)9.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.19
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.01%
ROE -75.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.68%
ROA(5y)-40.74%
ROE(3y)-71.18%
ROE(5y)-51.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.55
Quick Ratio 5.55
Altman-Z -4.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)445.09%
Cap/Depr(5y)331.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y29.47%
EPS Next 2Y15.61%
EPS Next 3Y5.67%
EPS Next 5Y9.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.02%
EBIT Next 3Y4.72%
EBIT Next 5Y4.61%
FCF growth 1Y30.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.8%
OCF growth 3YN/A
OCF growth 5YN/A